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Abstract 
The stem cell as the building block necessary for tissue reparation and homeostasis plays a major role in regenerative 
medicine. Their unique property of being pluripotent, able to control immune process and even secrete a whole army 
of anabolic mediators, draws interest. While new arthroscopic procedures and techniques involving stem cells have 
been established over the last decade with improved outcomes, failures and dissatisfaction still occur. Therefore, there 
is increasing interest in ways to improve the healing response. MSCs are particularly promising for this task given their 
regenerative potential. While methods of isolating those cells are no longer poses a challenge, the best way of appli-
cation is not clear. Several experiments in the realm of basic science and animal models have recently been published, 
addressing this issue, yet the application in clinical practice has lagged. This review provides an overview addressing 
the current standing of MSCs in the field of arthroscopic surgery.
Level of evidence IV.
Keywords: MSC, Stem cells, Arthroscopy, Scaffold
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The aging population in combination with an increas-
ingly active life style has led to new surgical challenges 
among orthopedic surgeons. As a result, there is a grow-
ing need for innovative approaches to substitute and 
repair tissue damaged through trauma or degenerative 
processes. Within the last decades, arthroscopic surgery 
has emerged as the state-of-the-art technology to address 
tendon, ligamentous, or chondral defects. Technologi-
cal advances in tools and materials continue to allow for 
an increasing number of procedures to be performed 
arthroscopically. Furthermore, biomechanical studies 
continue to reveal procedures that address defects by 
creating tissue reflective of their native anatomy. Unfor-
tunately, studies evaluating clinical applications have not 
yielded favorable outcomes at the same speed as the tech-
nical developments in the lab. This is evidenced by the re-
tear rate of rotator cuff repairs, which has remained over 
20  % [1, 2] or primary ACL reconstruction failure with 
5–15 % [3]. Thus, the focus in research has changed from 
only mechanical and technical points of the repair tech-
niques towards ways to improve the biological environ-
ment around the defect to create the best possible healing 
situations, with no regards between the older patient and 
young high-level athletes [4–8]. To meet this demand, 
tissue regeneration strategies that fulfill those advances 
and tasks are needed. MSCs may help to fill this void, 
as they have promising immunomodulatory properties, 
and are able to substitute damaged tissue and enhance 
the biologic healing process [9]. Currently, the isolation 
and, even more so, the different forms of application for 
SCs (SCs) in regenerative medicine to treat musculoskel-
etal disorders are issued to a growing extent. This review 
aims to provide a selective overview of the current indi-
cations of MSCs and their application form during clini-
cal routine. We focus on lately published data concerning 
human implementation of mainly bone marrow aspirate 
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MSC mighty or magic
The phenomena of regeneration and healing yield to the 
existence of building blocks needed to fulfill this chal-
lenge. In the late 90s, the concept of SC induced healing 
was theoretically postulated and gained more and more 
interest. Over the years, researchers were able to identify 
those cells and eventually cultivate and purify them. This 
practice has evolved to now encompass reinjection, start-
ing the age of SC investigation and therapy. The name 
autologous human MSC was first mentioned in the works 
of Caplan [10], describing a tissue progenitor cell that has 
the ability to differentiate into bone, tendon, cartilage, 
and ligament. MSCs are defined as non-hematopoietic, 
multipotent stromal cells that are responsible for main-
taining lifelong reproduction and self-renewal. In addi-
tion, they have to occupy a set of surface markers, such as 
the cluster of differentiation (CD)73, CD90, and CD105, 
and should lack expression of CD14, CD34, CD45, and 
human leucocyte antigen-DR (HLA-DR). Those markers 
are described as the minimum requirement [11]. Unfor-
tunately, the specific MSC marker is not yet found, but 
a lot of possible candidates [12–14] are still under inves-
tigation to find a quick and easy tool to identify MSCs. 
The stem cell itself is a non-specialized cell with the pos-
sibility to raise highly specific, adult descendants. It is 
important to distinguish between adult and embryotic or 
pluripotent and multipotent SCs. Embryonic stem cells 
(ESCs) are capable of unlimited, undifferentiated prolif-
eration [15, 16]. The remarkable difference between both 
is the proficiency of ESCs to differentiate into cells of all 
three germ layers, making them truly pluripotent. In con-
trast, adult MSCs cannot perform a germ layer change 
[17]. MSCs are assumed to exist in all tissues to provide 
a homeostasis and maintain integrity, which is why MSCs 
are now of interest as a resource for cellular therapeutic 
approaches.
ESCs as the omnifarious surrogate remain under inten-
sive investigation [18–20]. Despite their attractive capa-
bilities, ethical controversies regarding the use of ESCs 
have remained a difficult obstacle. Furthermore, they 
inhere a distinct oncogenic potential and are not present 
in adults.
In 2006, Takahashi and Yamanaka [21] were able to 
induce pluripotency in somatic cells through transfection 
with four embryonic transcription factors, creating ESC-
like cells. Those induced pluripotent stem cells (iPSC) 
provide a new opportunity for autologous cell therapy. 
Since they are considered as ESC-like cells, they harbor 
the inherent threat of developing malignancies [22]. As 
long as this risk is not clearly ruled out, routine clinical 
application is not viable.
In contrast to ESCs, adult SCs are proven to be much 
safer and have less ethical concerns. They can be col-
lected easily from any patient and reimplanted as autol-
ogous cells with no interference of the immune system. 
However, their limited differentiation potential deter-
mines the field of use. As by definition, adult SCs cannot 
undergo a germ layer change, and MSCs are a candidate 
of interest for tissue regeneration of cartilage, bone, and 
tendon. They are shown to be present and accessible in 
a variety of tissues, such as bone marrow, fat, synovial 
membrane, periosteum, and bursa [23]. It is not com-
pletely clear, yet in which tissue hosts the most promising 
MSCs for arthroscopic procedures.
From homing to healing immune effect of MSCs
What makes an MSC so interesting for the regenera-
tive medicine besides their ability to control local tissue 
homeostasis? Evidence of the immunomodulatory capa-
bilities of MSCs is growing and appears to be as crucial 
for cell therapy and healing processes. Furthermore, 
the infusion or injection of autologous MSCs does not 
result in host incompatibility reactions. This is likely 
due to low expression of MHC I and lacking expression 
of MHC class II along with co-stimulatory molecules, 
such as CD80, CD40, and CD86, making them a useful 
therapy [24] and simple to apply arthroscopically. They 
migrate chemotactically to the point of interest, rec-
ognizing inflammation or any other tissue injury with 
specific receptors [25]. This navigation program called 
homing is one of the main tasks to solve. So far, local 
delivery of the cells towards the defect has a beneficial 
outcome compared to systemic application that may be 
caused by a higher concentration of trophic factors and 
the entrapment of the cells in the microvasculature [26]. 
Beyond this, an ex  vivo expansion and proliferation of 
MSCs prior to replantation also shows negative effects 
most likely by a down regulation of adhesion ligands, 
such as CXCR4 and CCR1, necessary for the homing 
protocol. This problem can be overcome by an induced 
overexpression of CXCR4 [27] to reestablish their hom-
ing properties. Once the MSCs are in place, they do not 
only differentiate and substitute damaged or lost cells, 
but also secrete a variety of cytokines, demonstrating 
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anti-inflammatory activity and creating an anabolic 
microenvironment [28]. In vivo experiments and clinical 
trials confirmed the ability of MSCs to incorporate within 
a variety of injured tissues and differentiate into tissue-
specific cells and overtake lost cellular functions [29]. 
However, imaging and staining for MSCs have revealed 
no way of labeling or evidence for engraftment in long-
time, while a beneficial effect stays measurable [30, 31]. 
Only indirect response measurements like their release of 
soluble factors, for example, IGF-1, HGF, VEGF, IGF-2, 
bFGF, or pre-microRNAs, which protect host cells, pro-
mote cell proliferation, and enhance angiogenesis, can be 
determined [32]. Positive influence of paracrine signaling 
was already described and confirmed for the healing of 
cutaneous wounds [33] and ischemic heart failure [34]. It 
appears that endo- and paracrine functions have a higher 
impact potential than the cell differentiation and engraft-
ment itself [35, 36]. Supplementary MSCs have an immu-
nosuppressive and immunomodulation power proven 
in vitro and in vivo. They control the activation and pro-
liferation of immune cells, such as T lymphocyte [37] 
and cytotoxic T cells [38, 39] while releasing a variety of 
cytokines. With the knowledge of the anti-inflammatory 
effects, more and more clinical application options and 
treatment ideas are emerging. MSCs demonstrate the 
ability to enhance healing of rotator cuff tears [40], ACL 
ruptures [41], and chondral defects while appearing safe 
for use without serious adverse effects [42].
MSC sources for arthroscopic surgery
Adult MSCs can be harvested from a variety of mesen-
chymal tissues. Originally, MSCs were isolate from bone 
marrow aspirate of the iliac crest. This used to be the 
primary source of MSCs for orthopedic knee and shoul-
der surgeries. However, this invasive procedure is quite 
painful for the patient and increases the risk of infection 
slightly. Adipose-derived stem cells (ASC) have emerged 
as an alternative option given reduced morbidity with 
their isolation. These cells are usually obtained from the 
biological waste generated during liposuction or lipec-
tomy procedures by enzymatic digestion with collagenase 
followed by centrifugation and washing [43]. Notably, up 
to 500 times, more cells can be isolated from the same 
amount of fat tissue compared to an equivalent amount 
of bone marrow [44, 45]. For arthroscopic surgery, a local 
generation of MSCs during daily routine without the 
need of an additional extraction site is favorable. There-
fore, different techniques have been demonstrated. Maz-
zocca et  al. [46] published a procedure where during 
arthroscopic rotator cuff repair, bone marrow derived 
MSCs (bMSCs) can be successfully and safely harvested 
from the proximal humerus in humans and even rein-
jected to the repair site of the same patient to augment 
tendon-to-bone healing. Randelli et al. [47] were able to 
generate MSC samples from human supraspinatus ten-
don and long head of the biceps tendon in arthroscopic 
cuff repairs. Song et  al. [48] and Gohlke et  al. [49] iso-
lated MSCs from bursa tissue undergoing cuff surgery 
and characterized them for multilineage differentiation, 
pointing out their regeneration potential instead of being 
just surgical waste. As seen in the shoulder, MSCs are 
easily accessible during arthroscopic procedures of the 
knee. Beitzel et al. [50] showed an arthroscopic approach 
of bone marrow aspiration from the distal femur during 
ACL reconstruction without the need of any additional 
portal. In the course of development, we are now able to 
gain MSCs out of several tissues, including bone [51], fat 
[52], cartilage [53], muscle [54], tendon [55], ligaments 
[56], synovia [57], and subacromial bursa [49]. All of 
them have specific surface markers, capabilities of self-
renewal, and differentiation into several different mesen-
chymal tissues. Nonetheless, cells from each source have 
unique characteristics and differentiation potential [58], 
which needs further investigations to maximize use in 
specific clinical scenarios.
Ways of application
Two different strategies of cell-based therapy exist. The 
first approach is a simple local injection of a cell suspen-
sion that can be isolated or even purified ex  vivo prior 
to reinjection. The injected cells should then substitute 
damaged cells within a tissue to reconstitute its integrity 
and function. This procedure is also known as cell ther-
apy. The second way is called tissue engineering and is 
more complex. Here, cells are inoculated inside a three-
dimensional scaffold, other matrix carriers or even on 
sutures and screws, to compose a tissue-like construct, 
which is fixated on top or inside a defect to compensate 
for it. Several studies with an intra-articular injection of 
MSCs to improve healing capacity have been published. 
Positive effects using this technique have been seen in 
meniscal healing [59] and summarized by Yu et  al. [60] 
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and superior outcomes in rotator cuff repair [61] by 
adjunct MSC therapy. However, there is a lack of con-
sensus on whether the application of SCs alone leads to 
the enhancement of tissue regeneration and healing pro-
gression. For example, cell therapy alone is not as effec-
tive in regenerating larger tissue defects. In such cases, 
the approach of tissue engineering is a more promising 
strategy. In the process, tissue-specific cells are seeded 
on a scaffold that imitates the architecture of the tissue’s 
specific extracellular matrix. In the last decade, basic 
science has made great advances in tissue engineering 
research, resulting in in vitro composition of multiple dif-
ferent functional tissue constructs [62]. These constructs, 
or scaffolds, must be biocompatible, undergo some kind 
of degradation without being toxic, overtake mechani-
cal function, and facilitate bio-inductive properties [63]. 
Scaffolds are largely grouped as biologic or synthetic. To 
get replaced by regenerated tissue, biodegradable mate-
rials are in favor. The degradation velocity should be 
balanced to gain a steady state. While synthetic materi-
als can provide reproducible mechanical properties and 
predictable degradation, they usually are inert and do not 
interact with the loaded cells. In contrast, native extracel-
lular matrices present an alternative material option for 
scaffolds with some unique properties, as they are biolog-
ical active and able to control cell proliferation and dif-
ferentiation [64]. To improve the bioactivity of synthetic 
polymers, their surfaces have been modified to alter cell 
adhesion, migration, differentiation, and proliferation in 
recent studies. Thus, they were copolymerized with bio-
active materials [65–67] or even coated with cytokines 
[68]. Beitzel et  al. [69] addressed how different scaf-
folds behave and react in humans to extrapolate results 
obtained from experimental research. In their study, 
MSC’s adhesion, proliferation, and scaffold morphol-
ogy were evaluated by histologic analysis and electron 
microscopy. Nevertheless, tissue engineering therapy 
has so far only been tested excessively in animal models 
and did not perform the step towards patient beyond 
small clinical trials. However, applicability for tissue 
engineered constructs of large solid tissues in humans is 
still challenging [70]. While vascularization of the whole 
constructs remains an unsolved problem limiting the 
engraftment, tissue engineering was already success-
fully used in patients to substitute cartilage, representing 
avascular tissue [71]. Further investigations and research 
efforts are needed to facilitate wider usability in the near 
future.
From tissue to treatment—MSCs and arthroscopic 
procedure
The transition from innovation to administration of 
a biologically reinforced healing option suitable for 
use in the operation theater is a complex process that 
usually starts with an idea, followed by basic science 
before being used in clinical trials. Up to now, only a 
few clinical studies with a follow-up time frame have 
been published concerning the application of MSCs in 
arthroscopic surgery in humans. Here, we would like to 
summarize ongoing and upcoming stem cell projects 
and clinical studies during or after arthroscopic surgery 
in humans.
Upper extremity
Shoulder–rotator cuff tears are the most frequent shoul-
der problems [72] that require surgical intervention. The 
surgery is commonly performed arthroscopically with 
the aim of restoring the anatomic footprint. Despite 
improved surgical techniques [73] and the invention of 
new materials, the tendon-to-bone healing rate is unsat-
isfactory with a high number of re-tears and revisions 
[74]. The poor healing response is most likely multifac-
torial [8, 75] with a high impact of biological factors. 
Recently, Hernigou et al. demonstrated a reduced num-
ber of MSCs within the greater tuberosity of patients 
with symptomatic cuff tears [76] potentially indicating 
a weaker biologic response. This understanding suggests 
a greater need for biologic intervention rather than the 
traditional mechanical approach. Therefore, a procedure 
to augment rotator cuff repair with autologous puri-
fied MSCs at the time of surgery is attractive to facili-
tate improvements in tendon-to-bone healing. Gomes 
et al. [40] were the first group publishing a clinical trial 
with a small group of 14 patients investigating the influ-
ence of MSCs on rotator repairs. Included patients had a 
complete tear of the rotator cuff that was repaired with 
trans-osseous sutures through a mini-open procedure 
while augmenting the repair side with mononuclear SCs 
from iliac crest bone marrow aspirate. At a follow-up 
of at least 12  months, 12 of 14 tears had healed com-
pletely under radiologic control. Unfortunately, no con-
trol group was included in this study and the number of 
included patients was small, making it difficult to deter-
mine the efficacy of bMSCs as an adjunct to cuff repair 
at this time. However, these results suggest that MSC 
therapy has potential to enhance tendon repair in the 
future.
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Lower extremity
Knee—more than one million knee arthroscopies are 
performed annually in the US, with meniscal tears, chon-
dral lesions, and ligament ruptures represent the major-
ity of indications. Nevertheless, only limited potential 
indications for tissue restoration and regeneration are 
currently treated with SC application during an arthro-
scopic procedure. The arthroscopic management of 
injuries, especially in the knee, has improved with the 
progression of minimally invasive operative techniques 
and increasing knowledge of biomechanics and tissue 
engineering. However, the reality of the limited healing 
capacity of damaged structures and degenerative pro-
cesses remains. Therapeutic approaches that address the 
biological enhancement of healing are needed. Tears of 
the meniscus, a structure that is important to prevent 
joint degeneration, enhance stability, and improve con-
gruency combined with load distribution, represent the 
number one reason for an arthroscopic procedure [77]. 
Surgical repairs or partial resections of meniscal tears are 
the two options that the surgeon has, while suture repair 
is the only choice to maintain meniscal function. Unfor-
tunately, the post-operative failure rate of about 20 % and 
thus revisions are common. To improve the outcome 
after partial resection, Vangsness et  al. [59] designed a 
randomized double-blind-controlled clinical study with 
55 patients receiving intra-articular injections of human 
bMSCs within 10 days of arthroscopic partial meniscec-
tomy. Patients showed pain reduction and partial vol-
ume regeneration of the meniscus evaluated on MRIs. 
The calculated volume gain was significant compared 
with a baseline at follow-up of 24  months, demonstrat-
ing the utility of stem cell therapy in meniscus repair 
and an opportunity to preserve the knee cartilage. The 
known limitations of intrinsic healing potential of artic-
ular cartilage are attributed to the presence of small cell 
populations with low mitotic activity, the lack of vessels, 
and a reservoir of undifferentiated precursor-cells for 
substitution. A surgical approach is necessary to avoid 
further degeneration and development of osteoarthritis 
[78]. Although there are a variety of methods for surgi-
cal intervention, none are considered optimal. Disad-
vantages, such as poor structural quality of the repaired 
cartilage in bone marrow stimulation, donor site morbid-
ity in mosaicplasty, and loss of chondrogenic phenotype 
of expanded chondrocytes in autologous chondrocyte 
implantation, continue to pose challenges [79].
This leaves enough room for the SC therapy to prove 
itself as an effective novel option. Koh et  al. [80] dem-
onstrated positive effects of MSCs use in knee osteo-
arthritis by injecting previously harvested adipose 
tissue derived SCs during an arthroscopic lavage. They 
reported improved cartilage healing, reduced pain, and 
increased overall knee function scores at 24 month post-
operatively under MRI and partial second look arthros-
copy. Similar findings were reposted by Kim et  al. [81] 
in a recent study that compared the use of fibrin glue 
as a scaffold to contain the adipose-derived SCs within 
the defect. They concluded that there was no significant 
difference in clinical outcomes, but superior cartilage 
regeneration was observed arthroscopically. A com-
bined procedure of high tibial osteotomy (HTO) with 
arthroscopic-guided intra-articular injection of cultured 
bMSCs for patients suffering a unicompartmental osteo-
arthritis and genu varum has been published [80]. This 
prospective randomized controlled trial included 56 
patients who were divided in two groups, HTO + PRP/
HTO  +  PRP  +  MSCs. The authors reported and 
improved clinical outcomes, defect healing, and repair 
among their patients.
The manageable list of published literature con-
cerning of SC application within arthroscopic surgery 
shows that MSCs have already grasped the attention of 
the orthopedic community, but a major breakthrough 
is still lacking. Nonetheless, more trials are being 
conducted continuously. MSC applications for carti-
lage repair and tendon healing remain of high scien-
tific and clinical interest. However, currently available 
results suggest that MSCs are a safe treatment with an 
immense potential to enhance biological tissue regen-
eration (Figs. 1, 2). 
Conclusions
There is an increasing demand for MSC-based regen-
erative approaches to improve the biological healing 
response. Novel approaches have been investigated to 
augment tendon healing, enhance tissue regeneration, 
and cartilage repair arthroscopically. Various sources and 
delivery systems for MSCs, including simple injection or 
tissue engineering with scaffolds, are available and have 
been tested under clinical conditions, but the daily use 
of MSCs in arthroscopic surgery remains futuristic. Fur-
ther basic and clinical investigations are required before a 
procedure can be defined for routine use.
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